A randomised clinical trial evaluating the benefits of doxorubicin chemoembolisation versus systemic doxorubicin in patients with unresectable, advanced hepatocellular carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Doxorubicin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HEP-1
- 18 Dec 2013 Biomarkers information updated
- 29 Nov 2012 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 09 Jun 2010 New source identified and integrated (United Kingdom Clinical Research Network, 1337).